HEXO Corp. (TSX:HEXO) applied to list its shares on the NYSE on Friday, delivering on a promise it made to investors earlier this year. The application is still awaiting approval by the NYSE, but the announcement marks a milestone for the pot stock which prides itself on executing its commitments in a timely fashion.
“We committed to our shareholders that HEXO would seek a listing in the US by the end of 2018 and I am proud to say that we delivered,” HEXO CEO Sebastien St-Louis said in the press release. “We have a proven track record for our ability to execute and we will maintain it through our focus on developing and distributing innovative consumer-packaged cannabis products.”
Along with their NYSE application, HEXO also filed a short form base shelf prospectus to security regulatory authorities in both Canada and the United States. The prospectus, once approved, will enable the pot stock to make offers of up to $800 million in common shares for two years. A copy of the prospectus is available to investors on SEDAR.
HEXO continues to deliver on their promises to the Canadian market
The announcement to list on an American stock exchange was to be expected after HEXO and Molson-Coors (NYSE:TAP) (TSX:TPX) closed on their joint venture transaction in October. Through the joint venture, called Truss, the company will develop and distribute new non-alcoholic, cannabis-infused beverages to the Canadian market. Truss will operate as its own company, with its own board of directors and management team. The goal is to create a strong foundation for the future growth of the cannabis industry, a future that will hopefully include more legalized American cannabis markets.
Tapping into the American market should not be difficult for HEXO, seeing as they were one of the few Canadian cannabis companies to not only fulfill their cannabis orders in October but also refill their stock across the territories. While other companies were failing to meet the excessive recreational demand, HEXO was able to ship restocks ahead of schedule to stores across the country. If anything, this shows investors that HEXO is capable of withstanding the uncertainty of the cannabis market.
“Sales have been good, and we’ve been able to keep up,” St-Louis said of HEXO’s dependability. “We said we were ready; now we have proved it.”
HEXO’s dependable reputation might be paying off, as the company reported $5.2 million in revenue from the recreational market alone for the first quarter of 2019. But investors should not don any rose-colored glasses just yet. As the recreational market in Canada starts to level out, lower retail prices and share dilution may change the size of that number come the second quarter. There is nothing to say that HEXO will not continue to deliver on their promises, and the pot stock has big expansion plans for the future that could pay off for investors playing the long-game.
HEXO’s global expansion is starting in Greece, where the company announced their new manufacturing and distribution facilities in September. The pot stock partnered with Qannabos to capitalize on the eventual medical marijuana market in the country, but the plan is to create a “Eurozone” processing, production, and distribution based out of Greece that will give HEXO the first mover advantage they want in the European market. The first step will be the build-out of their 350,000 square foot facility while they wait for Greece to start licensing cannabis producers for the country officially.
There is no statement yet when Greece will start issuing licenses or if HEXO will even be one of the first to receive a license, but the company is situating itself in the best possible position. With an extensive portfolio and an American uplisting on the horizon, HEXO seems better off than most pot stocks at this time of year.